A Study of Hemp Hull WFI for IBS Diarrhea

Who can take part

• Prior diagnosis of bile acid diarrhea as documented by either; total bile acid in 48 hour stool excretion of 2337 micromoles per 48 hours, or; greater than 1000 micromoles per 48 hours with greater than 4% primary bile acids in stool, or; greater than 10% primary bile acid (CA and CDCA) in stool 48 hour collection, or; serum 7 alpha C4 greater than 52 ng/mL
• BMI <40 kg/m2
• Prior cholecystectomy, appendectomy, and tubal ligation or hysterectomy will all be permissible for participation in the study
• Participants receiving bile acid sequestrant will not be permitted to continue therapy. and need to stop one week before baseline test
• No use of oral antibiotics and NSAIDs for 2 weeks prior to study treatment

Who cannot take part

• Use of oral antibiotics and NSAIDs for 2 weeks prior to and during the entire 21 day study period
• Use of bile acid sequestrant for 1 week prior to and during the entire 21 day study period
• Diagnosis of gastrointestinal diseases that are associated with inflammation such as inflammatory bowel diseases and celiac disease or gastrointestinal infection in the prior 4 weeks
• Prior intestinal or colonic resection; note prior cholecystectomy, appendectomy, and tubal ligation or hysterectomy will all be permissible for participation in the study
• Participation in highly vigorous exercise such as running >5 miles per day in week prior to the permeability test
• Diabetes mellitus (type 1)
• Diabetes mellitus type 2 if taking metformin or GLP-1 agonist treatment (exenatide, liraglutide, semaglutide)
• Uncontrolled hypertension (with BP measured >140/90mmHg in the CRTU)
• BMI ≥40 kg/m2
• Chronic NSAID use (>1 day/week)